...
首页> 外文期刊>Arquivos de Neuro-Psiquiatria >Plasmapheresis in the treatment of myasthenia gravis: retrospective study of 26 patients
【24h】

Plasmapheresis in the treatment of myasthenia gravis: retrospective study of 26 patients

机译:血浆置换术治疗重症肌无力:26例患者的回顾性研究

获取原文

摘要

We analyzed the experience of Unicamp Clinical Hospital with plasma exchange (PE) therapy in myasthenia gravis (MG). About 17.8 % of a totality of MG patients had PE performed: 26 cases, 19 women and seven men. The mean age-onset of MG was 28 years, extremes 11 and 69. Minimum deficit observed in the group was graded IIb (O & G) or IIIa (MGFA scale). One patient had prethymectomy PE. In seven the procedures were performed due to myasthenic crisis and in 18 patients due to severe myasthenic symptoms or exacerbation of previous motor deficit. Two patients were also submitted to chronic PE considering refractoriness to other treatments. Twenty-six patients had 44 cycles of PE and 171 sessions. The mean number of sessions was 3.9 (SD ± 1.4) each cycle; median 5, extremes 2 and 6. The mean time by session was 106,5 minutes (SD ± 35.2); median 100.5 (extremes of 55 and 215). The mean volume of plasma exchanged in each session was 2396 ml (SD ± 561); median 2225 (extremes 1512 and 4500). Side effects occurred: reversible hypotension (seven cases), mild tremor or paresthesias (seven cases). Infection and mortality rates due to PE were zero. All patients had immediate benefit of each PE cycle and usually they also received prednisone or other immunosuppressors. Good acceptance of the procedure was observed in 80.7% of patients.
机译:我们分析了Unicamp临床医院在重症肌无力(MG)中进行血浆置换(PE)治疗的经验。 MG患者中约有17.8%进行过PE:26例,其中19名女性和7名男性。 MG的平均发病年龄为28岁,极端11和69。该组中观察到的最小缺陷为IIb(O&G)或IIIa(MGFA量表)。 1例患者行胸腺切除术。其中有7例因肌无力危象而进行手术,18例因严重的肌无力症状或先前运动功能障碍加重而进行了手术。考虑到其他治疗方法的顽固性,两名患者也接受了慢性PE治疗。 26例患者进行了44个PE周期和171个疗程。每个周期的平均会话数为3.9(SD±1.4);中位数5,极限2和6。平均每次锻炼时间为106.5分钟(SD±35.2);中位数为100.5(极端值为55和215)。每个阶段交换的血浆平均体积为2396 ml(SD±561);中位数2225(极端1512和4500)。发生的副作用:可逆性低血压(七例),轻度震颤或感觉异常(七例)。 PE引起的感染和死亡率为零。所有患者在每个PE周期都立即受益,通常他们也接受泼尼松或其他免疫抑制剂的治疗。在80.7%的患者中观察到对该程序的良好接受。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号